HC Wainwright Reiterates Rating on Nuvectis Pharma, Inc. $NVCT
Key Points
- HC Wainwright now rates Nuvectis Pharma, Inc. ($NVCT) "buy" with a $13.00 target.
- The Street's average $NVCT price target is $17.40 (Strong Buy).
- $NVCT last traded around $10.71.
HC Wainwright reiterated its rating on Nuvectis Pharma, Inc. ($NVCT) to a "buy" rating, with a price target of $13.00 in a recent research note.
Nuvectis Pharma, Inc. ($NVCT) Stock
Nuvectis Pharma, Inc. Earnings
Analysts Set New Price Targets
About Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.